Are you Dr. Loghin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Monica Loghin, MD is a board certified neurologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Arizona. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at HoustonResidency, Neurology, 2000 - 2003- University of Texas Health Science Center at HoustonInternship, Internal Medicine, 1999 - 2000
University of Medicine and Pharmacy ‘Gr T Popa” Iasi Class of 1983
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2006 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- American Board of Psychiatry and Neurology Neurology
- Join now to see all
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting Start of enrollment: 2017 Jan 20
Publications & Presentations
PubMed
- 68 citationsLeptomeningeal disease and breast cancer: The importance of tumor subtypeSausan Abouharb, Joe Ensor, Monica Loghin, Ruth L. Katz, Stacy L. Moulder
Breast Cancer Research and Treatment. 2014-07-20 - 29 citationsPosterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective studyCarlos Kamiya-Matsuoka, Asif M. Paker, Linda Chi, Ayda Youssef, Sudhakar Tummala
Journal of Neuro-Oncology. 2016-02-22 - 45 citationsA randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao Pei Weathers, Xiaosi Han, Diane D. Liu, Charles A. Conrad, Mark R. Gilbert
Journal of Neuro-Oncology. 2016-07-12
Professional Memberships
- Member
